Company intelligence / Profile preview

Cita NeuroPharmaceuticals

Mississauga, Ontario, Canada

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Lead asset CNP1512 (levodopa methyl-ester + carbidopa effervescent formulation) entered Phase 3 with positive safety/efficacy signals; CNP3381 for neuropathic pain entered Phase 2, showing promising proof-of-concept efficacy and tolerance. At acquisition, pipeline consisted of CNS-focused small molecules with 6 clinical programs, later discontinued/absorbed after acquisition.

Therapeutic areas: NeurologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Chiesi Farmaceutici (licensee, marketed CNP1512 in Italy)

Beyond the preview

Go deeper on Cita NeuroPharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cita NeuroPharmaceuticals.

Explore the full profile